圣湘生物
(688289)
| 流通市值：88.89亿 | | | 总市值：88.89亿 |
| 流通股本：5.75亿 | | | 总股本：5.75亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,252,372,952.77 | 834,318,517.89 | 437,346,014.85 | 1,641,533,008.19 |
| 营业收入 | 1,252,372,952.77 | 834,318,517.89 | 437,346,014.85 | 1,641,533,008.19 |
| 二、营业总成本 | 1,190,121,965.26 | 767,843,840.43 | 373,874,252.96 | 1,396,281,013.98 |
| 营业成本 | 395,311,499.01 | 239,271,031.02 | 116,708,807.49 | 397,479,157.73 |
| 税金及附加 | 9,755,661.7 | 5,946,133.95 | 2,550,902.27 | 11,532,986.16 |
| 销售费用 | 445,840,997.18 | 304,582,183.1 | 149,057,410.58 | 601,703,210.65 |
| 管理费用 | 177,920,283.38 | 114,144,409.66 | 56,725,333.44 | 220,526,563.06 |
| 研发费用 | 183,884,586.95 | 119,257,583.5 | 56,531,896.35 | 229,114,830.76 |
| 财务费用 | -22,591,062.96 | -15,357,500.8 | -7,700,097.17 | -64,075,734.38 |
| 其中:利息费用 | 21,176,572.3 | 13,830,225.06 | 6,593,760.65 | 23,291,424.56 |
| 其中:利息收入 | 53,403,118.47 | 36,269,614.67 | 16,947,202.72 | 86,818,264.87 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 79,226,747.02 | 78,896,970.38 | 613,304.28 | 48,574,301.3 |
| 加:投资收益 | -23,010,624.61 | -14,113,137.14 | -7,360,567.49 | -55,237,813 |
| 资产处置收益 | -11,245,070.07 | -11,433,901.15 | -2,244,233.13 | -2,946,565.51 |
| 资产减值损失(新) | -524,306.94 | -2,026,154.58 | 482,225.51 | -29,650,010 |
| 信用减值损失(新) | -9,261,921.47 | -10,194,636.66 | -7,135,752.07 | -32,031,533.05 |
| 其他收益 | 14,639,774.67 | 8,320,540.88 | 4,240,761.65 | 29,310,979.32 |
| 四、营业利润 | 112,075,586.11 | 115,924,359.19 | 52,067,500.64 | 203,271,353.27 |
| 加:营业外收入 | 476,126.98 | 391,355.49 | 264,280.92 | 4,388,453.22 |
| 减:营业外支出 | 24,269,562.37 | 20,422,902.35 | 1,216,730.84 | 32,575,842.94 |
| 五、利润总额 | 88,282,150.72 | 95,892,812.33 | 51,115,050.72 | 175,083,963.55 |
| 减:所得税费用 | 10,631,440.71 | 14,583,404.37 | 9,323,462.82 | 21,159,180.97 |
| 六、净利润 | 77,650,710.01 | 81,309,407.96 | 41,791,587.9 | 153,924,782.58 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 77,650,710.01 | 81,309,407.96 | 41,791,587.9 | 153,924,782.58 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 104,048,408.07 | 98,017,339.57 | 49,739,326.83 | 198,937,411.42 |
| 少数股东损益 | -26,397,698.06 | -16,707,931.61 | -7,947,738.93 | -45,012,628.84 |
| 扣除非经常损益后的净利润 | 57,518,029.6 | 53,704,256.98 | 49,664,685.87 | 166,797,183.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.18 | 0.17 | 0.08 | 0.34 |
| (二)稀释每股收益 | 0.18 | 0.17 | 0.08 | 0.34 |
| 八、其他综合收益 | -6,765,641.52 | -4,939,415.42 | -1,865,099.45 | -8,298,918.92 |
| 归属于母公司股东的其他综合收益 | -6,765,641.52 | -4,939,415.42 | -1,865,099.45 | -8,621,663.92 |
| 九、综合收益总额 | 70,885,068.49 | 76,369,992.54 | 39,926,488.45 | 145,625,863.66 |
| 归属于母公司股东的综合收益总额 | 97,282,766.55 | 93,077,924.15 | 47,874,227.37 | 190,315,747.5 |
| 归属于少数股东的综合收益总额 | -26,397,698.06 | -16,707,931.61 | -7,947,738.93 | -44,689,883.84 |
| 公告日期 | 2026-10-29 | 2026-08-27 | 2026-04-30 | 2026-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |